MX2010005119A - Corticosteroides para tratar la diarrea inducida por la epotilona o los derivados de epotilona. - Google Patents

Corticosteroides para tratar la diarrea inducida por la epotilona o los derivados de epotilona.

Info

Publication number
MX2010005119A
MX2010005119A MX2010005119A MX2010005119A MX2010005119A MX 2010005119 A MX2010005119 A MX 2010005119A MX 2010005119 A MX2010005119 A MX 2010005119A MX 2010005119 A MX2010005119 A MX 2010005119A MX 2010005119 A MX2010005119 A MX 2010005119A
Authority
MX
Mexico
Prior art keywords
epothilone
corticosteroids
treat
induced diarrhea
derivative induced
Prior art date
Application number
MX2010005119A
Other languages
English (en)
Spanish (es)
Inventor
Paul M J Mcsheehy
Anandhi Ranganathan Johri
Dirk Weber
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010005119A publication Critical patent/MX2010005119A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MX2010005119A 2007-11-09 2008-10-15 Corticosteroides para tratar la diarrea inducida por la epotilona o los derivados de epotilona. MX2010005119A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98663507P 2007-11-09 2007-11-09
PCT/US2008/079936 WO2009061587A1 (en) 2007-11-09 2008-10-15 Corticosteroids to treat epothilone or epothilone derivative induced diarrhea

Publications (1)

Publication Number Publication Date
MX2010005119A true MX2010005119A (es) 2010-05-27

Family

ID=40087318

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005119A MX2010005119A (es) 2007-11-09 2008-10-15 Corticosteroides para tratar la diarrea inducida por la epotilona o los derivados de epotilona.

Country Status (11)

Country Link
US (1) US20100267682A1 (enExample)
EP (1) EP2222286A1 (enExample)
JP (1) JP2011503075A (enExample)
KR (1) KR20100096077A (enExample)
CN (1) CN101848708B (enExample)
AU (1) AU2008325016A1 (enExample)
BR (1) BRPI0820338A2 (enExample)
CA (1) CA2703792A1 (enExample)
MX (1) MX2010005119A (enExample)
RU (1) RU2010123028A (enExample)
WO (1) WO2009061587A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014052237A1 (en) 2012-09-26 2014-04-03 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
EP2945628B1 (en) * 2013-01-15 2020-04-15 Aragon Pharmaceuticals, Inc. Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer
US11061027B2 (en) * 2016-09-27 2021-07-13 Mayo Foundation For Medical Education And Research Materials and methods for evaluating and treating cancer
KR20240096623A (ko) 2017-10-16 2024-06-26 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
US10705435B2 (en) 2018-01-12 2020-07-07 Globalfoundries Inc. Self-referencing and self-calibrating interference pattern overlay measurement
US11686576B2 (en) 2020-06-04 2023-06-27 Kla Corporation Metrology target for one-dimensional measurement of periodic misregistration
US11796925B2 (en) 2022-01-03 2023-10-24 Kla Corporation Scanning overlay metrology using overlay targets having multiple spatial frequencies
US12032300B2 (en) 2022-02-14 2024-07-09 Kla Corporation Imaging overlay with mutually coherent oblique illumination
US12422363B2 (en) 2022-03-30 2025-09-23 Kla Corporation Scanning scatterometry overlay metrology
US12487190B2 (en) 2022-03-30 2025-12-02 Kla Corporation System and method for isolation of specific fourier pupil frequency in overlay metrology
US12669327B2 (en) 2022-11-23 2026-06-30 Kla Corporation System and method for suppression of tool induced shift in scanning overlay metrology
US12235588B2 (en) 2023-02-16 2025-02-25 Kla Corporation Scanning overlay metrology with high signal to noise ratio
US12704790B2 (en) 2023-04-04 2026-08-11 Kla Corporation System and method for determining overlay measurement of a scanning target

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1231894A (zh) * 1998-04-14 1999-10-20 陈水清 止泻栓
EP1372650B1 (en) * 2001-03-19 2008-11-19 Novartis AG Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
US6974818B2 (en) * 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
AU2003264822A1 (en) * 2002-10-11 2004-05-04 Dana-Farber Cancer Institute Inc Epothilone derivatives for the treatment of multiple myeloma
BRPI0513825A (pt) * 2004-07-26 2008-05-20 Novartis Ag combinações de epotilona

Also Published As

Publication number Publication date
KR20100096077A (ko) 2010-09-01
BRPI0820338A2 (pt) 2017-05-02
RU2010123028A (ru) 2011-12-20
CA2703792A1 (en) 2009-05-14
CN101848708A (zh) 2010-09-29
AU2008325016A1 (en) 2009-05-14
US20100267682A1 (en) 2010-10-21
CN101848708B (zh) 2013-01-02
JP2011503075A (ja) 2011-01-27
WO2009061587A1 (en) 2009-05-14
EP2222286A1 (en) 2010-09-01

Similar Documents

Publication Publication Date Title
WO2010088409A3 (en) Methods of neuroprotection using neuroprotective steroids and a vitamin d
WO2009031040A3 (en) Compounds with anti-cancer activity
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
IL222695A0 (en) Methods, compositions, and kits for the treatment of matrix mineralization disorders
MX2009009428A (es) Analogos de ciclopamina heterociclicos y metodos de uso de los mismos.
TW200738263A (en) ANG2 and VEGF inhibitor combinations
PH12017500930A1 (en) Hsp90 inhibitor combinations
BR112012009306A2 (pt) método para regeneração de mielina em um paciente
WO2010081032A3 (en) Steroidal compositions
TN2010000214A1 (en) Methods for treating obesity and obesity related diseases and disorders
WO2007144152A3 (en) Extended step-down estrogen regimen
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
AU2008232453A8 (en) Methods and compositions for reduction of side effects of therapeutic treatments
CL2009001011A1 (es) Uso del compuesto 21-metoxi-17a-acetoxi-11ß-(4-n,n­-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona (cdb-4124) para tratar el cancer de mama; y uso de la combinacion de cdb-4124 con un inhibidor de aromatasa.
MY155418A (en) Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2010014595A3 (en) Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders
WO2008073509A3 (en) Compositions and methods for treating a neoplasm
MX339116B (es) Tratamiento de esclerosis tuberosa.
EP2425874A3 (en) Use of a vitamin D compound and an additional therapeutic agent for the treatment of cancer
GB2475660A (en) Methods and kits for treating cluster headache disorders
MX2010002667A (es) Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
IL231631A0 (en) Preparations and method for the treatment of senile farsightedness, mild farsightedness and abnormal astigmatism
PH12014500596A1 (en) Plant steroids and uses thereof
TN2009000136A1 (en) Sequential combination therapy
IL204194A0 (en) Natural brassinosteroids for use for treating hyperproliferation, treating proliferative diseases and reducing adverse effects of steroid dysfunction in mammals, pharmaceutical composition and its use

Legal Events

Date Code Title Description
FA Abandonment or withdrawal